CA-TERIDION
23.5.2019 14:02:12 CEST | Business Wire | Press release
Teridion , the company delivering the only global public cloud-based WAN service , today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service.
For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications such as voice and video to see latency improvements of up to 30 percent and file transfer throughput increases of up to 500 percent. As always, the Cisco Meraki and Teridion solution is secured with Cisco’s market-leading security capabilities and managed in the cloud.
The Teridion cloud WAN service is a simple, snap-in integration with Cisco Meraki MX enterprise security and SD-WAN appliances that brings carrier grade Internet and WAN performance to broadband and dedicated Internet access connections. Teridion is available at a fraction of the cost of carrier circuits, and is backed with an SLA. Partners that offer the combined Cisco Meraki and Teridion solution will be able to engage more opportunities and offer a compelling new service to their installed base.
“This news is tremendous validation for the differentiated WAN offering we launched late last year,” said Pejman Roshan, VP of Products and Marketing for Teridion. “We have been working closely with Cisco Meraki on this deep integration, and together the combined solution makes it easy to deploy a secure and high performance WAN that is 100-percent cloud managed. Together, Cisco Meraki and Teridion enable businesses with regional, nationwide, or global WANs to drastically improve the performance of business critical applications, whether they are hosted in corporate data centers, SaaS applications, or deployed across various cloud providers.”
“As enterprises prepare for a cloud-ready application environment, they are laser focused on providing the best application performance for staff and customers in remote locations and branch offices,” said Raviv Levi, director of product management at Cisco Meraki. “The combined Cisco Meraki and Teridion solution offers rich SD-WAN and security capabilities at the WAN edge that are tightly integrated with a high performance and cost-effective WAN service delivered over cost-effective broadband or dedicated Internet access. This brings better reliability and consistency to the enterprise WAN across multiple sites, as well as high performance access to all SaaS applications and cloud workloads.”
Teridion also announced today the general availability of Teridion for Enterprise, the industry’s first solution that eliminates the reliability and performance gap introduced by the reliance on the public Internet middle-mile and exposed by the massive shifts to the cloud and SD-WAN. By tightly integrating with a leading SD-WAN solution such as the Cisco Meraki SD-WAN, Teridion unites centralized cloud management, enterprise-grade security, and ultra-fast WAN performance in a single, tightly integrated offering. As a result, enterprises leverage a solution that is optimized for delivery performance, reliability, control, and visibility end to end across the public Internet.
Teridion’s public cloud-based WAN service is powered by Teridion Curated Routing , an innovative and cloud native approach to routing that draws on the power of deep learning and brings hierarchical and centralized routing to enterprise networking. Teridion Curated Routing radically improves WAN, application, and SaaS performance. Originally launched delivering interoperability with today’s most popular SD-WAN offerings, today’s announcement marks the first deep, end-to-end integration with a leading SD-WAN solution.
Learn more about Teridion’s deep integration with Cisco Meraki in the Cisco Meraki Marketplace at https://apps.meraki.io/details/teridion-for-enterprise/ , or at teridion.com/meraki .
Availability and Pricing
Teridion for Cisco Meraki is available today from authorized Teridion resellers. Pricing starts at $50 per site per month. More details about how to buy can be found at https://www.teridion.com/meraki .
About Teridion
Founded in 2013, Teridion enables faster and more reliable Internet with Teridion Curated Routing, radically improving Internet performance up to 2X - 20X, anywhere in the world. Teridion for Enterprise combines the performance, reliability, and SLAs of legacy WAN technologies such as MPLS with the agility and elastic scalability of the cloud. The company is backed by leading venture investors including Jerusalem Venture Partners, Magma Venture Partners and Singtel Innov8, and is relied on by leading SaaS providers such as Atlassian, Box, Egnyte, Merrill Corp., and many others. Teridion is headquartered in San Francisco, with international offices in Petah Tikva, Israel. For more information, visit www.teridion.com or email info@teridion.com .
Teridion is a registered trademark of Teridion in the United States and other countries. All rights reserved. All other company and product names are either trademarks or registered trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005161/en/
Contact:
Dan Spalding dspalding@teridion.com (408) 960-9297
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom